MedPath

The Clinical Efficacy of Rezūm Therapy Versus Bipolar Trans-urethral Resection of the Prostate for Treatment Benign Prostatic Hyperplasia

Not Applicable
Completed
Conditions
Prostatic Hyperplasia
Interventions
Procedure: Rezum procedure
Procedure: B-TURP procedure
Registration Number
NCT06116370
Lead Sponsor
Ain Shams University
Brief Summary

We aimed to compare the efficacy and safety of Rezūm therapy and bipolar transurethral resection of prostate (B-TURP) for the management of benign prostatic hyperplasia (BPH) of 50-120gm size.

Detailed Description

For decades, Transurethral resection of the prostate (TURP) was the gold standard surgical intervention for small and moderate prostates, however it has high morbidity and prolonged hospital stay. In contrast to monopolar TURP (M-TURP), where prolonged resection carries the risk of transurethral resection (TUR) syndrome, bipolar transurethral resection of prostate (B-TURP), especially in large prostates was a promising procedure for urologists, but unfortunately, the morbidity rate of B-TURP remains high \[4\]. Therefore, newer minimally invasive procedures have been introduced to provide alternative surgical options to TURP.

Rezūm is a radiofrequency made water vapour thermal treatment. It has recently been added to the international guidelines as a choice for medical treatment resistant lower urinary tract symptoms (LUTS). The AUA and Canadian Urological Association (CUA) guidelines now add water vapour therapy as a treatment option for BPH patients with small prostate size \<80 gm and for those wishing to maintain antegrade ejaculation. While they still offer no clear recommendation to Rezūm use for those with large prostates. Early studies on this topic have found out promising results.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
100
Inclusion Criteria
  • Patients aged 50-80 years
  • prostate volumes of 50-120 ml
  • sexually active
  • severe LUTS
  • [Q max] of <10 ml/s
  • [IPSS] of >20)
  • failed medical treatment with alpha blockers
Exclusion Criteria
  • prostate cancer
  • Neurogenic bladder
  • urethral stricture
  • urinary bladder stone
  • previous prostatic surgery.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BPH patients treated with Rezum procedureRezum procedurePatients aged 50-80 years with prostate volumes of 50-120 ml, sexually active, and have severe LUTS treated with Rezum procedure
BPH patients treated with B-TURP procedureB-TURP procedurePatients aged 50-80 years with prostate volumes of 50-120 ml, sexually active, and have severe LUTS treated with Rezum procedure
Primary Outcome Measures
NameTimeMethod
Measurement of The International Prostate Symptom score (IPSS) in both groupsfor each case in both groups the investigator assess IPSS at 6, 12, and 24 months after procedures through study completion, an average of 2 years

After 6, 12, and 24 months of operation, the questioner is performed. Minimum :0 / Maximum : 35 Total score: 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic

Measurement of The International Index of Erectile Function (IIEF) in both groupsfor each case in both groups the investigator assess IIEF at 6, 12, and 24 months after procedures through study completion, an average of 2 years

After 6, 12, and 24 months of operation, the questioner is performed. The IIEF-5 score is the sum of the ordinal responses to the 5 items. 22-25: No erectile dysfunction 17-21: Mild erectile dysfunction 12-16: Mild to moderate erectile dysfunction 8-11: Moderate erectile dysfunction 5-7: Severe erectile dysfunction

The operative time of both groupsfor each case in both groups the investigator assess the time of operation from induction of anaesthesiatill the end of the operation through study completion, an average of 2 years

the operative time was measured by minutes in both groups.

Post operative hospital stay time in both groupsfor each case in both groups the investigator assess the hospital time from the day of admission of the patient in hospital to do intervention till discharge from hospital through study completion, an average of 2 years

the Post operative hospital stay time was measured by hours in both groups.

Measurement of Post operative residual urine (PVR)for each case in both groups the investigator assess prostate size at 6, 12 and 24 months after procedures through study completion, an average of 2 years

PVR was measured by ml by pelvi abdominal ultra sound in both groups. Normal ranges are below 150 ml of urine.

Measurement of The Quality of Life (QoL) in both groupsfor each case in both groups the investigator assess QoLat 6, 12, and 24 months after procedures through study completion, an average of 2 years

After 6, 12, and 24 months of operation, the questioner is performed. Minimum :0 means delighted / Maximum : 5 means unhappy

Measurement of The Maximum Urinary flow rate (Qmax) in both groupsfor each case in both groups the investigator assess Qmax at 6, 12, and 24 months after procedures through study completion, an average of 2 years

After 6, 12, and 24 months of operation, the procedure is performed. Qmax is measured by (ml/sec) Normal values are described as a Qmax above 15 ml/sec and below 10 ml/sec is considered abnormal

Concentration of The Prostatic specific antigen (PSA) in both groupsfor each case in both groups the investigator measures PSA at 6, 12, and 24 months after procedures through study completion, an average of 2 years

After 6, 12, and 24 months of operation, the procedure is performed. PSA is measured by ng/ml PSA levels of 4.0 ng/mL and lower were considered

Measurement of The Prostate sizefor each case in both groups the investigator assess prostate size at 24 months after procedures through study completion, an average of 2 years

the prostate size was measured by grams by Trans-rectal ultra sound

Incidence of The catheter duration post operative in both groupsfor each case in both groups the investigator assess the catheter duration from the end of the operation till removal through study completion, an average of 2 years

The catheter duration was measured by days in both groups.

Secondary Outcome Measures
NameTimeMethod
Incidence of complicationsthrough two years

For each case in both groups the investigator assess the safety using incidence of complications by The Clavien-Dindo system

Trial Locations

Locations (1)

Ain Shams University

🇪🇬

Cairo, Abbassia, Egypt

© Copyright 2025. All Rights Reserved by MedPath